Dr. Choudhury discussed glioma care advances, highlighting IDH inhibitors like vorasidenib and the need for next-gen sequencing for non-canonical mutations. He cited ongoing trials at Tampa General and emphasized surgery, brachytherapy, and continued research to address tumor heterogeneity.